RxDoctor Payments Data

Samir Shah, MD

Pulmonary Disease · Newton, NJNPI 1083691000

Payments from drug & device makers

$750in general payments, 2019–2025

Across 25 payments — averaging $29.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$148
  • Abbott$134
  • Amarin Pharma, Inc.$131
  • Dexcom, Inc.$96
  • Itamar Medical Inc$89
  • Medtronic$73
  • plus $78 from 3 others

What the payments were for

  • Food & beverage$67690%
  • Entertainment$7410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$750 in reported general payments places this provider in the 30th percentile of 472 pulmonary disease providers in New Jersey.

See all pulmonary disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$420,203
Medicare patients
1,093
Services billed
4,724

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter446$454,294
Breo ElliptaFluticasone/Vilanterol235$155,202
Pirfenidone37$149,015
Breztri AerosphereBudesonide/Glycopyr/Formoterol145$129,710
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr160$128,231
EliquisApixaban83$92,391
Fluticasone-SalmeterolFluticasone Propion/Salmeterol436$70,394
Spiriva RespimatTiotropium Bromide79$68,581
Incruse ElliptaUmeclidinium Bromide97$60,579
Advair HfaFluticasone Propion/Salmeterol99$49,945
Arnuity ElliptaFluticasone Furoate122$45,601
Stiolto RespimatTiotropium Br/Olodaterol Hcl48$41,592
OzempicSemaglutide24$30,658
XareltoRivaroxaban15$18,050
SymbicortBudesonide/Formoterol Fumarate42$17,558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$15$843,9081,060 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 472 pulmonary disease providers in New Jersey.

Other pulmonary disease in Newton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →